Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Resverlogix ( (TSE:RVX) ).
Resverlogix Corp. has confirmed it will miss the March 31, 2026 deadline to file its annual audited financial statements and related disclosures for the year ended December 31, 2025, due to delays in starting the audit process. The company and its external auditor have committed additional resources and now expect, though cannot guarantee, to complete the audit and filings by April 10, 2026, while management remains under an insider trading blackout.
The Alberta Securities Commission is reviewing Resverlogix’s application for a management cease trade order, which, if granted, would restrict trading by the CEO and CFO but allow public trading in its shares to continue. Resverlogix says there has been no undisclosed material change, confirms it is not subject to insolvency proceedings, and will keep investors informed through bi-weekly default status updates until the filings are brought up to date.
More about Resverlogix
Resverlogix Corp. is a Calgary-based late-stage biotechnology company focused on epigenetics, developing first-in-class therapies that regulate the expression of disease-causing genes. Its lead candidate, apabetalone, is being evaluated for cardiovascular disease, associated comorbidities, and post COVID-19 conditions, with shares listed on the Toronto Stock Exchange under the symbol RVX.
Average Trading Volume: 40,108
Technical Sentiment Signal: Hold
Current Market Cap: C$34.75M
For detailed information about RVX stock, go to TipRanks’ Stock Analysis page.